The recent meta-analysis with regards to patients with CRPC that were treated with enzalutamide, darolutamide, or apalutamide, clarified that second-generation AR antagonists are associated with a significantly increased risk of cardiovascular events including stroke, heart failure, and peripheral vascular disease [33]. The gene discussed is AR; the disease is peripheral vascular disease.